Clinical trial reportJournal of managed care & specialty pharmacyPublished
Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Clinical trial report
- Venue
- Journal of managed care & specialty pharmacy
- Published
- Topic
- Public health
- Subject terms
- Humans; Multiple Myeloma; Neoplasm, Residual; Dexamethasone; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Models, Economic; Aged; Cost-Benefit Analysis; Health Care Costs; Drug Costs; United States
- PubMed ID
- 42726291
- PubMed Central ID
- PMC13621899
- Open access
- Yes, free to read
- Added to directory
- Source checked